03rd week of 2020 patent applcation highlights part 22 |
Patent application number | Title | Published |
20200017504 | ANTIMICROBIALS AND METHODS OF MAKING AND USING SAME | 2020-01-16 |
20200017505 | NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF | 2020-01-16 |
20200017506 | METHODS FOR INHIBITING FASCIN | 2020-01-16 |
20200017507 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | 2020-01-16 |
20200017508 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | 2020-01-16 |
20200017509 | NOVEL POLYMORPHIC FORMS OF CYCLO (-HIS-PRO) | 2020-01-16 |
20200017510 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | 2020-01-16 |
20200017511 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | 2020-01-16 |
20200017512 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | 2020-01-16 |
20200017513 | (E)-1-(4-(DIMETHYLAMINO)BUT-2-ENOYL)PYRROLIDIN-3-YL 4-((3-ISOPROPYL-5-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-7-YL)AMINO)PIPERIDINE-1-- CARBOXYLATE FOR INHIBITING CDK7 | 2020-01-16 |
20200017514 | ADAMANTANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | 2020-01-16 |
20200017515 | Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes | 2020-01-16 |
20200017516 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | 2020-01-16 |
20200017517 | PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | 2020-01-16 |
20200017518 | Bis-Cyclic Carbonate Molecule with Bis(1,3)-Dioxin-Dione Structure | 2020-01-16 |
20200017519 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | 2020-01-16 |
20200017520 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | 2020-01-16 |
20200017521 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | 2020-01-16 |
20200017522 | SECO MACROLIDE COMPOUNDS | 2020-01-16 |
20200017523 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | 2020-01-16 |
20200017524 | TRICYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | 2020-01-16 |
20200017525 | Thienopyridine Carboxamides as Ubiquitin-Specific Protease Inhibitors | 2020-01-16 |
20200017526 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | 2020-01-16 |
20200017527 | CRYSTALLINE FORMS OF A JANUS KINASE INHIBITOR | 2020-01-16 |
20200017528 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE1 INHIBITOR | 2020-01-16 |
20200017529 | NOVEL THIENOTHIOPHENE COMPOUNDS FOR LONG-ACTING INJECTABLE COMPOSITIONS AND RELATED METHODS | 2020-01-16 |
20200017530 | MUSCARINIC RECEPTOR AGONISTS | 2020-01-16 |
20200017531 | OXABOROLE ESTERS AND USES THEREOF | 2020-01-16 |
20200017532 | SILICON-CONTAINING COMPOUND FOR RESISTANCE TO HEPATITIS C VIRUS INFECTION | 2020-01-16 |
20200017533 | Organosilane Compounds and Methods of Making and Using the Same | 2020-01-16 |
20200017534 | CRYSTALLINE FORMS | 2020-01-16 |
20200017535 | METAL COMPLEXES AND METHODS OF PREPARING THE SAME | 2020-01-16 |
20200017536 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | 2020-01-16 |
20200017537 | LINCOSAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS ANTIMICROBIAL AGENT | 2020-01-16 |
20200017538 | Compounds, Compositions, and Methods for Coloring Edible Materials | 2020-01-16 |
20200017539 | PROCESS OF MAKING REGADENOSON AND NOVEL POLYMORPHS THEREOF | 2020-01-16 |
20200017540 | METHOD FOR THE SITE-SPECIFIC ENZYMATIC LABELLING OF NUCLEIC ACIDS IN VITRO BY INCORPORATION OF UNNATURAL NUCLEOTIDES | 2020-01-16 |
20200017541 | Novel Triterpene-Glycoside as Sweetener or Sweetener Enhancer | 2020-01-16 |
20200017542 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | 2020-01-16 |
20200017543 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | 2020-01-16 |
20200017544 | Detection and Quantification of Glycosylated Peptides | 2020-01-16 |
20200017545 | Methods and Reagents for Purification of Proteins | 2020-01-16 |
20200017546 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | 2020-01-16 |
20200017547 | PROBIOTIC MOLECULES FOR REDUCING PATHOGEN VIRULENCE | 2020-01-16 |
20200017548 | Growth Hormone Releasing Peptides | 2020-01-16 |
20200017549 | NOVEL a4B7 PEPTIDE ANTAGONISTS | 2020-01-16 |
20200017550 | PEPTIDES AND METHODS OF USING SAME | 2020-01-16 |
20200017551 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | 2020-01-16 |
20200017552 | DE NOVO DESIGNED HEMAGGLUTININ BINDING PROTEINS | 2020-01-16 |
20200017553 | Foot and Mouth Disease Virus (FMDV) Consensus Proteins, Coding Sequences Therefor and Vaccines Made Therefrom | 2020-01-16 |
20200017554 | SELF-ASSEMBLING PROTEIN NANOPARTICLES WITH BUILT-IN SIX-HELIX BUNDLE PROTEINS | 2020-01-16 |
20200017555 | ZIKA VIRUS VACCINE | 2020-01-16 |
20200017556 | MUTANT PORES | 2020-01-16 |
20200017557 | UNSTRUCTURED NON-REPETITIVE POLYPEPTIDES HAVING LCST BEHAVIOR | 2020-01-16 |
20200017558 | MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM | 2020-01-16 |
20200017559 | NOVEL RECOMBINANT PROTEIN UK 114 IN STABLE POLYMER FORM FOR USE IN THE TREATMENT, DIAGNOSIS AND PREVENTION OF MALIGNANT SOLID AND SYSTEMIC TUMOURS | 2020-01-16 |
20200017560 | CCN3 AND CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE | 2020-01-16 |
20200017561 | VARIANT SURVIVIN VACCINE FOR TREATMENT OF CANCER | 2020-01-16 |
20200017562 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISORDERS AND ALZHEIMER'S DISEASE AND IMPROVING NORMAL MEMORY | 2020-01-16 |
20200017563 | STRUCTURE-BASED PEPTIDE INHIBITORS THAT TARGET THE TAU VQIINK FIBRILLIZATION SEGMENT | 2020-01-16 |
20200017564 | EMBRYONIC ANGIOGENESIS MARKERS AND DIAGNOSTIC AND THERAPEUTIC STRATEGIES BASED THEREON | 2020-01-16 |
20200017565 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | 2020-01-16 |
20200017566 | HEPCIDIN AND MINI-HEPCIDIN ANALOGUES AND USES THEROF | 2020-01-16 |
20200017567 | NPRA AGONISTS, COMPOSITIONS, AND USES THEREOF | 2020-01-16 |
20200017568 | HIGH AFFINITY MAGE-A1-SPECIFIC TCRS AND USES THEREOF | 2020-01-16 |
20200017569 | CARBOHYDRATE CONTENT OF CTLA4 MOLECULES | 2020-01-16 |
20200017570 | POLYPEPTIDES, CELLS, AND METHODS INVOLVING ENGINEERED CD16 | 2020-01-16 |
20200017571 | TNFRSF14 / HVEM PROTEINS AND METHODS OF USE THEREOF | 2020-01-16 |
20200017572 | VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION | 2020-01-16 |
20200017573 | I DOMAIN CHIMERIC ANTIGEN RECEPTOR SPECIFIC TO ICAM-1 | 2020-01-16 |
20200017574 | POLYMERIC FORMS OF H-NOX PROTEINS | 2020-01-16 |
20200017575 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF | 2020-01-16 |
20200017576 | HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ | 2020-01-16 |
20200017577 | TDP-43 Specific Binding Molecules | 2020-01-16 |
20200017578 | AGGLUTINATION OF GANGLIOSIDES FOR TREATING ALZHEIMER'S DISEASE | 2020-01-16 |
20200017579 | ANTI-TAU ANTIBODIES AND METHODS OF USE | 2020-01-16 |
20200017580 | MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS | 2020-01-16 |
20200017581 | METHODS FOR TREATING CHRON'S DISEASE USING AN ANTI-IL23 ANTIBODY | 2020-01-16 |
20200017582 | IMMUNOASSAY METHOD USING ANTI-HUMAN BNP FRAGMENT (4-32) ANTIBODY | 2020-01-16 |
20200017583 | ANTI-GPR20 ANTIBODY | 2020-01-16 |
20200017584 | Modulation of Stimulatory and Non-stimulatory Myeloid Cells | 2020-01-16 |
20200017585 | ANTIBODY TO FIBROSIS-RELATED MOLECULE AND MEDICAL APPLICATION THEREOF | 2020-01-16 |
20200017586 | USE OF IMMUNE CHECKPOINT MODULATORS IN COMBINATION WITH ANTIGEN-SPECIFIC T CELLS IN ADOPTIVE IMMUNOTHERAPY | 2020-01-16 |
20200017587 | B7-DC BINDING ANTIBODY | 2020-01-16 |
20200017588 | MODULAR TETRAVALENT BISPECIFIC ANTIBODY PLATFORM | 2020-01-16 |
20200017589 | ANTI-VISTA ANTIBODIES AND FRAGMENTS | 2020-01-16 |
20200017590 | NOVEL ANTI-TRKB ANTIBODIES | 2020-01-16 |
20200017591 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | 2020-01-16 |
20200017592 | ANTI-IL36R ANTIBODIES | 2020-01-16 |
20200017593 | METHOD OF PRODUCING ANTIBODIES WITH N-GLYCOSIDE-LINKED SUGAR CHAINS LACKING FUCOSYLATION | 2020-01-16 |
20200017594 | IMMUNOMODULATORY ANTIBODIES | 2020-01-16 |
20200017595 | BINDING MOLECULES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL | 2020-01-16 |
20200017596 | MONOCLONAL ANTIBODIES ACTIVATING CD40 AND USES THEREOF | 2020-01-16 |
20200017597 | TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMYELITIS OPTICA | 2020-01-16 |
20200017598 | USE OF C5AR ANTAGONISTS | 2020-01-16 |
20200017599 | ANTI-C5a RECEPTOR ANTIBODIES | 2020-01-16 |
20200017600 | VARIANTS OF CD38 ANTIBODY AND USES THEREOF | 2020-01-16 |
20200017601 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES | 2020-01-16 |
20200017602 | PLASMA KALLIKREIN BINDING PROTEINS | 2020-01-16 |
20200017603 | NOVEL USES OF PCSK9 INHIBITORS AND RELATED MEDICATIONS | 2020-01-16 |